Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exec Chat: Medtronic Neuromodulation Approaches Inflection Point

Executive Summary

Medtech Insight talked to Ashwini Sharan, the new chief medical officer for Medtronic's neuromodulation business, and and Nnamdi Njoku, the president of the business, to learn about the company's vision for neuromodulation technology and how the company can leverage its particular strengths make these therapies more effective and accessible.

You may also be interested in...

Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator

The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.

Abbott’s Plan For DBS Depression Therapy Wins FDA’s Breakthrough Designation

Abbott continued St. Jude Medical’s prior research on deep brain stimulation for treating depression and has advanced the technology far enough that the US FDA now believes it could be a breakthrough treatment for treatment-resistant depression.

NeuroMetrix Gets FDA De Novo Authorization For Neuromodulation Device To Treat Fibromyalgia

NeuroMetrix plans to market the prescription-based Quell in the fourth quarter to US rheumatologists and pain medicine physicians.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts